| Identification | Back Directory | [Name]
JZL 195 | [CAS]
1210004-12-8 | [Synonyms]
JZL 195
CS-1586
JZL-195;JZL 195;JZL195
4-nitrophenyl 4-(3-phenoxybenzyl)piperazine-1-carboxylate
4-[(3-Phenoxyphenyl)methyl]-1-piperazinecarboxylic acid 4-nitrophenyl ester
1-Piperazinecarboxylic acid, 4-[(3-phenoxyphenyl)methyl]-, 4-nitrophenyl ester | [Molecular Formula]
C24H23N3O5 | [MDL Number]
MFCD18382122 | [MOL File]
1210004-12-8.mol | [Molecular Weight]
433.46 |
| Chemical Properties | Back Directory | [Boiling point ]
581.8±50.0 °C(Predicted) | [density ]
1.303±0.06 g/cm3(Predicted) | [storage temp. ]
Sealed in dry,Store in freezer, under -20°C | [solubility ]
DMSO: ≥5mg/mL at warmed | [form ]
powder | [pka]
6.13±0.10(Predicted) | [color ]
white to beige |
| Hazard Information | Back Directory | [Description]
Fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL) mediate the hydrolysis of the endocannabinoids arachidonoyl ethanolamide (AEA) and 2-arachidonoylglycerol (2-AG), respectively. JZL 195 is a potent inhibitor of both FAAH and MAGL (IC50s = 2 and 4 nM, respectively). It poorly inhibits neuropathy target esterase and ABHD6 and does not inhibit other brain serine hydrolases. JZL 195 displays time-dependent inhibition of FAAH and MAGL in vivo, consistent with a covalent mechanism of activation. The in vivo inhibitory actions of JZL 195 against FAAH and MAGL are comparable to those of the selective inhibitors PF-3845 and JZL 184 , respectively. Through its inhibitory actions, JZL 195 simultaneously augments brain levels of AEA and 2-AG, producing antinociceptive, cataleptic, and hypomotility effects like those produced by direct CB1 agonists. | [Uses]
JZL195 is a selective and efficacious dual FAAH/MAGL inhibitor with IC50 of 13 nM and 19 nM for mouse brain FAAH and MAGL respectively. | [storage]
Store at -20°C |
|
|